AstraZeneca PLC (AZN)vsBrightSpring Health Services, Inc. Common Stock (BTSG)
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
BTSG
BrightSpring Health Services, Inc. Common Stock
$57.40
0.00%
HEALTHCARE · Cap: $11.97B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 343% more annual revenue ($60.44B vs $13.65B). AZN leads profitability with a 17.2% profit margin vs 2.3%. AZN trades at a lower P/E of 27.5x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
BTSG
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for BTSG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Earnings expanding 359.8% YoY
Revenue surging 25.6% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
2.3% margin — thin
Operating margin of 3.4%
Elevated debt levels
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : BTSG
The strongest argument for BTSG centers on EPS Growth, Revenue Growth. Revenue growth of 25.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : BTSG
The primary concerns for BTSG are Profit Margin, Operating Margin, Debt/Equity. A P/E of 79.2x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while BTSG is a growth play — different risk/reward profiles.
BTSG carries more volatility with a beta of 1.87 — expect wider price swings.
BTSG is growing revenue faster at 25.6% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 53/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
BrightSpring Health Services, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
BrightSpring Health Services, Inc. (BTSG) is a leading provider of home and community-based health services, specializing in the care of diverse patient populations, including individuals with intellectual and developmental disabilities and those in need of rehabilitation. The company is committed to delivering personalized, high-quality care through a skilled workforce, which contributes to improved patient outcomes and enhances quality of life. With a focus on strategic investments in innovative technologies and a robust approach to value-based care, BrightSpring is well-positioned to thrive in the dynamic healthcare environment and capitalize on emerging market opportunities.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?